Literature DB >> 28052488

Lymphatic Endothelial Cells Produce M-CSF, Causing Massive Bone Loss in Mice.

Wensheng Wang1,2, Hua Wang2,3, Xichao Zhou2, Xing Li2, Wen Sun2, Michael Dellinger4, Brendan F Boyce2,5, Lianping Xing2,5.   

Abstract

Gorham-Stout disease (GSD) is a rare bone disorder characterized by aggressive osteolysis associated with lymphatic vessel invasion within bone marrow cavities. The etiology of GSD is not known, and there is no effective therapy or animal model for the disease. Here, we investigated if lymphatic endothelial cells (LECs) affect osteoclasts (OCs) to cause a GSD osteolytic phenotype in mice. We examined the effect of a mouse LEC line on osteoclastogenesis in co-cultures. LECs significantly increased receptor activator of NF-κB ligand (RANKL)-mediated OC formation and bone resorption. LECs expressed high levels of macrophage colony-stimulating factor (M-CSF), but not RANKL, interleukin-6 (IL-6), and tumor necrosis factor (TNF). LEC-mediated OC formation and bone resorption were blocked by an M-CSF neutralizing antibody or Ki20227, an inhibitor of the M-CSF receptor, c-Fms. We injected LECs into the tibias of wild-type (WT) mice and observed massive osteolysis on X-ray and micro-CT scans. Histology showed that LEC-injected tibias had significant trabecular and cortical bone loss and increased OC numbers. M-CSF protein levels were significantly higher in serum and bone marrow plasma of mice given intra-tibial LEC injections. Immunofluorescence staining showed extensive replacement of bone and marrow by podoplanin+ LECs. Treatment of LEC-injected mice with Ki20227 significantly decreased tibial bone destruction. In addition, lymphatic vessels in a GSD bone sample were stained positively for M-CSF. Thus, LECs cause bone destruction in vivo in mice by secreting M-CSF, which promotes OC formation and activation. Blocking M-CSF signaling may represent a new therapeutic approach for treatment of patients with GSD. Furthermore, tibial injection of LECs is a useful mouse model to study GSD.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE RESORPTION; GORHAM-STOUT DISEASE; LYMPHATIC ENDOTHELIAL CELLS; M-CSF; OSTEOCLASTS

Mesh:

Substances:

Year:  2017        PMID: 28052488      PMCID: PMC5413433          DOI: 10.1002/jbmr.3077

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  36 in total

1.  Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts.

Authors:  S Takeshita; K Kaji; A Kudo
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract.

Authors:  Irina Arnaoutova; Hynda K Kleinman
Journal:  Nat Protoc       Date:  2010-03-11       Impact factor: 13.491

3.  The Gorham-Stout syndrome (Gorham's massive osteolysis). A report of six cases with histopathological findings.

Authors:  G Möller; M Priemel; M Amling; M Werner; A S Kuhlmey; G Delling
Journal:  J Bone Joint Surg Br       Date:  1999-05

4.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.

Authors:  T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

Review 5.  Osteoclast precursors, RANKL/RANK, and immunology.

Authors:  Lianping Xing; Edward M Schwarz; Brendan F Boyce
Journal:  Immunol Rev       Date:  2005-12       Impact factor: 12.988

6.  Relationships between trabecular bone remodeling and bone vascularization: a quantitative study.

Authors:  O Barou; S Mekraldi; L Vico; G Boivin; C Alexandre; M H Lafage-Proust
Journal:  Bone       Date:  2002-04       Impact factor: 4.398

7.  A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.

Authors:  Hiroaki Ohno; Kazuo Kubo; Hideko Murooka; Yoshiko Kobayashi; Tsuyoshi Nishitoba; Masabumi Shibuya; Toshiyuki Yoneda; Toshiyuki Isoe
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

8.  Plasma VEGF determination in disseminated lymphangiomatosis-Gorham-Stout syndrome: a marker of activity? A case report with a 5-year follow-up.

Authors:  Jean-Louis Dupond; Laurent Bermont; Michel Runge; Marjolaine de Billy
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

9.  Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.

Authors:  F Arai; T Miyamoto; O Ohneda; T Inada; T Sudo; K Brasel; T Miyata; D M Anderson; T Suda
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

10.  M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.

Authors:  Yoshiaki Kubota; Keiyo Takubo; Takatsune Shimizu; Hiroaki Ohno; Kazuo Kishi; Masabumi Shibuya; Hideyuki Saya; Toshio Suda
Journal:  J Exp Med       Date:  2009-04-27       Impact factor: 14.307

View more
  15 in total

Review 1.  The endothelium-bone axis in development, homeostasis and bone and joint disease.

Authors:  Jan Tuckermann; Ralf H Adams
Journal:  Nat Rev Rheumatol       Date:  2021-09-03       Impact factor: 20.543

2.  Attenuated Joint Tissue Damage Associated With Improved Synovial Lymphatic Function Following Treatment With Bortezomib in a Mouse Model of Experimental Posttraumatic Osteoarthritis.

Authors:  Wensheng Wang; Xi Lin; Hao Xu; Wen Sun; Echoe M Bouta; Michael J Zuscik; Di Chen; Edward M Schwarz; Lianping Xing
Journal:  Arthritis Rheumatol       Date:  2019-01-05       Impact factor: 10.995

3.  Lymphatics in bone arise from pre-existing lymphatics.

Authors:  Marco Monroy; Anna L McCarter; Devon Hominick; Nina Cassidy; Michael T Dellinger
Journal:  Development       Date:  2020-04-20       Impact factor: 6.868

4.  Gorham-Stout Disease of the Shoulder: Clinical, Pathologic and Therapeutic Considerations.

Authors:  Mohamad Y Fares; Jawad Fares; Youssef Fares; Joseph A Abboud
Journal:  Arch Bone Jt Surg       Date:  2020-01

Review 5.  Modeling Rare Bone Diseases in Animals.

Authors:  Charles A O'Brien; Roy Morello
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

6.  VEGF-C promotes the development of lymphatics in bone and bone loss.

Authors:  Devon Hominick; Asitha Silva; Noor Khurana; Ying Liu; Paul C Dechow; Jian Q Feng; Bronislaw Pytowski; Joseph M Rutkowski; Kari Alitalo; Michael T Dellinger
Journal:  Elife       Date:  2018-04-05       Impact factor: 8.140

7.  Combined neodymium-doped yttrium aluminum garnet laser and sclerotherapy in Gorham-Stout syndrome.

Authors:  Maria Reipschläger; Uwe Huebner; Joerg Seemann; Heinz Kutzner; Peter H Hoeger
Journal:  JAAD Case Rep       Date:  2018-04-30

8.  Massive Axial and Appendicular Skeletal Deformities in Connection with Gorham-Stout Syndrome.

Authors:  Ali Al Kaissi; Sami Bouchoucha; Mohammad Shboul; Vladimir Kenis; Franz Grill; Rudolf Ganger; Susanne Gerit Kircher
Journal:  Medicines (Basel)       Date:  2019-05-07

9.  Lymphatic muscle cells contribute to dysfunction of the synovial lymphatic system in inflammatory arthritis in mice.

Authors:  Qianqian Liang; Li Zhang; Hao Xu; Jinlong Li; Yan Chen; Edward M Schwarz; Qi Shi; Yongjun Wang; Lianping Xing
Journal:  Arthritis Res Ther       Date:  2021-02-19       Impact factor: 5.156

10.  Insights into the mechanism of vascular endothelial cells on bone biology.

Authors:  Ying Yin; Qingming Tang; Mengru Xie; Li Hu; Lili Chen
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.